Lumos Diagnostics Expands Medicare Coverage for FebriDx®

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an update.

Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing diagnostic solutions that improve patient care, integrate into care pathways, and deliver value to the healthcare system.

YTD Price Performance: -37.50%

Average Trading Volume: 1,360,987

Technical Sentiment Signal: Buy

Current Market Cap: A$18.71M

For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.